House ephedra hearings
This article was originally published in The Tan Sheet
Executive Summary
Energy & Commerce Committee ephedra investigation builds steam, with plans to hold two days of hearings in late July. Sports league heads, ephedra manufacturers, FDA reps likely will be called to testify. Committee chair Billy Tauzin (D-La.) and others send July 1 follow-up letter requesting FDA provide records on foreign ephedra investigations, AEs received since Sept. 30, 2001 close date of RAND report. Letter also requests records relating to FDA communications on the Boozer-Daly study often cited by ephedra proponents, and records relating to Hicksville, NY-based Phoenix Labs, which manufactured Xenadrine RFA-1 for Cytodyne. Investigation was launched in February with letters to McClellan, Cytodyne (1"The Tan Sheet" March 3, 2003, p. 9). Hearings for related inquiry into supplements marketed to children unlikely until after August recess...
You may also be interested in...
Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter
The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.